Efficacy of Triphaladi churna (orally) along with Mustadi rasakriya anjan and Triphaladi churna (orally) alone in the management of Dry type of age related macular degeneratio

Not Applicable

Completed

• Conditions: Health Condition 1: H353- Degeneration of macula and posterior pole

• Registration Number: CTRI/2022/05/042658
• Lead Sponsor: Government Akhandanand Ayurveda College

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2023-09-04
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

1. Age group between 40-90 years of either sex.

2. visual acuity for distance vision between 6/6 to 6/60 and for near vision N/6 to N/36 with glasses.

3. The patient presenting with signs and symptoms of ARMD (DRY TYPE) like Difficulty in day vision, Diminished vision, Distorted vision, Perception of black spots in the field of vision, Perception of flashes of light, Problem for adaptation with dim light, presence of macular drusens , focal hyperpigmentation , pale area of retinal pigment atrophy in retina will be included in the study.

Exclusion Criteria

1. Age less than 40 years and more than 90 years.

2. visual acuity for distance vision less than 6/60 and for near vision more than N/36 with glasses

3. Contraindicated for Anjan

Sama Avastha of Netra (Doshas associated with aam) ,Ghana Pichchila Srava ( Thick/dense , sliminess discharge ), Ati Kandu ( Excessive itching ),Swayathu ( Swelling ),Mlan Netrata (Tired eye)

SYSTAMIC EXCLUSION:

Chronic debilitating diseases like Renal disorder, Liver disorder, Hiv, Carcinoma .

OPHTHALMIC EXCLUSION:

Wet type of ARMD, Glaucoma ,Mature cataract ,Pan retinal degenerations ,Chronic conjunctivitis ,Keratoconjunctivitis ,Hypertensive retinopathy ,Diabetic retinopathy , Any type of ocular injury e.g. blunt trauma, including chemical injury

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To reduce difficulty in vision, dimnished vision and distored vision in ARMD patientsTimepoint: 58 days

Secondary Outcome Measures

Name	Time	Method
To improve quality of life with the improve vision.Timepoint: 88 days